News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA to Review Arcoxia, Merck & Co., Inc.'s (Jobs) Follow-Up to Vioxx
March 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
A Food and Drug Administration panel in April will review Merck's Arcoxia, its follow-up to the controversial painkiller Vioxx, which was pulled from the market in 2004 following safety concerns.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Merck & Co.
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
Drug pricing
Pfizer To Offer Drugs at a Discount in Agreement with US Government
September 30, 2025
·
2 min read
·
Dan Samorodnitsky
IN PARTNERSHIP WITH ELEMENT
Webinar: Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
September 30, 2025
·
1 min read
·
BioSpace Insights
Regulatory
FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints
September 30, 2025
·
2 min read
·
Tristan Manalac
